Meridian Bioscience, Inc., a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for gastrointestinal and respiratory infectious diseases, and elevated blood lead levels worldwide. The company operates through Diagnostics and Life Science segments. The Diagnostics segment offers testing platforms, including real-time PCR amplification under the Revogene brand; isothermal DNA amplification under the Alethia brand; lateral flow immunoassay using fluorescent chemistry under the Curian brand; rapid immunoassay under the ImmunoCard and ImmunoCard STAT! brands; enzyme-linked immunoassays under the PREMIER brand; anodic stripping voltammetry under the LeadCare and PediaStat brands; and urea breath testing for H. pylori under the BreathID brand. This segment also offers gastrointestinal assays, including tests for C. difficile, H. pylori, and certain foodborne pathogens; respiratory illness assays, such as tests Group A strep, mycoplasma pneumonia, influenza, and pertussis; and blood chemistry assays for testing elevated levels of lead in blood. It sells products through direct sales force and independent distributors to acute care hospitals, reference laboratories, outpatient clinics, and physician office laboratories. The Life Science segment offers bulk antigens, antibodies, PCR/qPCR reagents, nucleotides, and bioresearch reagents used by in vitro diagnostic manufacturers, as well as researchers in immunological and molecular tests for human, animal, plant, and environmental applications. The company has a strategic collaboration with DiaSorin Inc. to sell H. pylori tests. Meridian Bioscience, Inc. was incorporated in 1976 and is headquartered in Cincinnati, Ohio.
IPO Year:
Exchange: NASDAQ
Website: meridianbioscience.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/7/2022 | $28.00 → $30.00 | Buy | HC Wainwright & Co. |
| 11/15/2021 | $27.00 → $28.00 | Buy | HC Wainwright & Co. |
| 8/9/2021 | $30.00 → $27.00 | Buy | HC Wainwright & Co. |
Fastest customizable press release news feed in the world
Mr. Harris was the lead battery responsible engineer at SpaceX, leading the engineering team that developed the battery systems of the Falcon 9 rocket, Cargo Dragon, and Crew Dragon spacecraft Appointment to Advisory Council bolsters VivoPower's power systems and battery engineering expertise across its sovereign AI data center platform, including operational Nordic sites as well as for Tembo, its electric vehicle business LONDON, June 02, 2026 (GLOBE NEWSWIRE) -- VivoPower PLC (NASDAQ:VIVO) ("VivoPower" or the "Company"), a B Corp-certified global developer and owner of powered land and data center infrastructure for AI compute applications, today announced the appointment of Porter Har
New tenant(s) expected to further improve data center economics for VivoPower beyond its current annual $31 million in revenues and $10 million in EBITDA—transaction expected to be finalized by June 30, 2026 Short list follows the completion of a lease bidding process, which fielded firm proposals that were stronger and broader than anticipated Board also received and evaluated unsolicited offers to acquire the asset at a premium to VivoPower's acquisition price, which were rejected Board considers strategic value to be materially higher, given the asset has amongst the lowest power costs for data centers in Europe and the world Operational 41.5MW with a further 40MW expected to be ene
VivoPower's presentation is scheduled for Wednesday, May 20, 2026, at 11:00 AM ET LONDON, May 14, 2026 (GLOBE NEWSWIRE) -- VivoPower PLC (NASDAQ:VIVO) ("VivoPower" or the "Company"), a B Corp-certified global developer and owner of powered land and data center infrastructure for AI compute applications, announced today that its senior management team will present at KBRA's European Data Centers Event. Alex Cuppage, Chief Investment Officer, will represent VivoPower at the event on Wednesday, 20 May 2026. VivoPower's presentation is scheduled from 11:00 AM ET to 11:45 AM ET. The panel will be moderated by Killian Walsh, Managing Director, Structured Finance at KBRA, alongside other indust
MIAMI, May 06, 2026 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 92nd Emerging Growth Conference on May 6 & 7, 2026. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: Questions@EmergingGrowth.com For updates, follow us on Twitter. Presenting today – Wednesday, May 6, 2026 9:00Virtual Lobby opens.Register for the Conference. If you already registered, go
MIAMI, May 05, 2026 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 91st Emerging Growth Conference on May 6 & 7, 2026. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: Questions@EmergingGrowth.com For updates, follow us on Twitter Day 1 - WednesdayMay 6, 2026 9:00Virtual Lobby opens.Register for the Conference. If you already registered, go back to the re
VivoPower's main presentation is scheduled for Wednesday, May 6, 2026, at 4:25 PM ET LONDON, April 29, 2026 (GLOBE NEWSWIRE) -- VivoPower PLC (NASDAQ:VIVO) ("VivoPower" or the "Company"), a B Corp-certified global developer and owner of powered land and data center infrastructure for AI compute applications, announced today that its senior management team will present at the Emerging Growth Conference. VivoPower's main presentation is scheduled for Wednesday, May 6, 2026, from 4:25 PM ET to 4:55 PM ET. The presentation will be led by Kevin Chin, Executive Chairman and CEO, and Alex Cuppage, Chief Investment Officer. The formal presentation will feature a fireside chat-style Q&A session,
Demand Response Program Targeted to Add USD 1.9 Million in Annualized EBITDA, with No Incremental Capex or Opex Required Full Year Annualized EBITDA Impact Expected from Fiscal Year 2027 Enrolment in Demand Response Program Complementary to AI Tenant Operations LONDON, April 27, 2026 (GLOBE NEWSWIRE) -- VivoPower PLC (NASDAQ:VIVO) ("VivoPower" or the "Company"), a leading B Corp-certified global developer and owner of powered land and data center infrastructure for AI compute applications, today announced that its 41.5 MW Mo i Rana data center in Northern Norway has prequalified 30 MW of capacity into Statnett SF's ancillary services markets, providing balancing capacity to the Nordi
Multiple inbound inquiries from AI neocloud operators and hyperscalers for Mo i Rana Norway operational 41.5MW data center which has a pathway to over 80MW, subject to regulatory approval Powered by 100% renewable hydroelectric energy at below US$0.035/kWh among the lowest power costs for data centers in Europe New tenant(s) expected to further improve data center economics for VivoPower beyond its current annual $31 million in revenues and $10 million in EBITDA Formal selective, competitive RFP process launched to evaluate commercial terms, operational alignment, and strategic fit of potential tenants LONDON, UK / OSLO, NORWAY, April 23, 2026 (GLOBE NEWSWIRE) -- VivoPower PLC (NASDAQ
Transaction closed and fully funded for the $41 million acquisition, with no additional public equity raising required for the transaction Company expects to achieve immediate group-level EBITDA profitability on a pro forma basis — a step change transformation from pre-acquisition levels Facility capacity confirmed at 41.5MW with an additional 40MW expansion subject to regulatory approval, providing a pathway to over 80MW LONDON, UK / OSLO, NORWAY, April 21, 2026 (GLOBE NEWSWIRE) -- VivoPower PLC (NASDAQ:VIVO) ("VivoPower" or the "Company"), a B Corp-certified global developer and owner of powered land and data center infrastructure for AI compute applications, today announced the closi
Ms. Mustafa brings a track record from a 23-year tenure at Microsoft, where she headed Global Sales & Partnerships for Industrial Metaverse Core, in the Cloud & AI division of Microsoft Based between New York and Abu Dhabi, she was also formerly head of global partnerships for Core 42, which is part of G42, the Abu Dhabi headquartered AI group backed by Mubadala, Microsoft, Silverlake, and the Dalio Family Office LONDON, April 07, 2026 (GLOBE NEWSWIRE) -- VivoPower PLC (NASDAQ:VIVO) ("VivoPower" or the "Company"), a B Corp-certified global developer and owner of powered land and data center infrastructure for AI compute applications, today announced the appointment of Khadija Mustafa to
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
3 - VivoPower PLC (0001681348) (Issuer)
4 - MERIDIAN BIOSCIENCE INC (0000794172) (Issuer)
4 - MERIDIAN BIOSCIENCE INC (0000794172) (Issuer)
4 - MERIDIAN BIOSCIENCE INC (0000794172) (Issuer)
4 - MERIDIAN BIOSCIENCE INC (0000794172) (Issuer)
4 - MERIDIAN BIOSCIENCE INC (0000794172) (Issuer)
4 - MERIDIAN BIOSCIENCE INC (0000794172) (Issuer)
4 - MERIDIAN BIOSCIENCE INC (0000794172) (Issuer)
4 - MERIDIAN BIOSCIENCE INC (0000794172) (Issuer)
4 - MERIDIAN BIOSCIENCE INC (0000794172) (Issuer)
6-K - VivoPower PLC (0001681348) (Filer)
6-K/A - VivoPower PLC (0001681348) (Filer)
6-K - VivoPower PLC (0001681348) (Filer)
6-K - VivoPower PLC (0001681348) (Filer)
15-12G - MERIDIAN BIOSCIENCE INC (0000794172) (Filer)
10-Q - MERIDIAN BIOSCIENCE INC (0000794172) (Filer)
EFFECT - MERIDIAN BIOSCIENCE INC (0000794172) (Filer)
EFFECT - MERIDIAN BIOSCIENCE INC (0000794172) (Filer)
EFFECT - MERIDIAN BIOSCIENCE INC (0000794172) (Filer)
EFFECT - MERIDIAN BIOSCIENCE INC (0000794172) (Filer)
Live FDA approvals issued by the Food and Drug Administration and FDA breaking news
For Immediate Release: December 10, 2021 The U.S. Food and Drug Administration today announced the following actions taken in its ongoing response effort to the COVID-19 pandemic: On December 9, 2021, the FDA updated the SARS-CoV-2 Viral Mutations: Impact on COVID-19 Tests web page to share the latest information. The update added new information about the Meridian Bioscience, Inc. Revogene SARS-CoV-2 test, inc
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
HC Wainwright & Co. reiterated coverage of Meridian Bioscience with a rating of Buy and set a new price target of $30.00 from $28.00 previously
HC Wainwright & Co. reiterated coverage of Meridian Bioscience with a rating of Buy and set a new price target of $28.00 from $27.00 previously
HC Wainwright & Co. reiterated coverage of Meridian Bioscience with a rating of Buy and set a new price target of $27.00 from $30.00 previously
HC Wainwright & Co. reiterated coverage of Meridian Bioscience with a rating of Buy and set a new price target of $30.00 from $32.00 previously
HC Wainwright reiterated coverage of Meridian Bioscience with a rating of Buy and set a new price target of $32.00 from $34.00 previously
HC Wainwright & Co. reiterated coverage of Meridian Bioscience with a rating of Buy and set a new price target of $32.00 from $34.00 previously
Piper Sandler resumed coverage of Meridian Bioscience with a rating of Overweight and set a new price target of $34.00 from $26.00 previously
HC Wainwright & Co. reiterated coverage of Meridian Bioscience with a rating of Buy and set a new price target of $34.00 from $30.00 previously
This live feed shows all institutional transactions in real time.
SC 13G/A - MERIDIAN BIOSCIENCE INC (0000794172) (Subject)
SC 13D/A - MERIDIAN BIOSCIENCE INC (0000794172) (Subject)
SC 13G/A - MERIDIAN BIOSCIENCE INC (0000794172) (Subject)
SC 13D/A - MERIDIAN BIOSCIENCE INC (0000794172) (Subject)
SC 13D/A - MERIDIAN BIOSCIENCE INC (0000794172) (Subject)
SC 13D/A - MERIDIAN BIOSCIENCE INC (0000794172) (Subject)
SC 13D/A - MERIDIAN BIOSCIENCE INC (0000794172) (Subject)
SC 13D/A - MERIDIAN BIOSCIENCE INC (0000794172) (Subject)
SC 13D/A - MERIDIAN BIOSCIENCE INC (0000794172) (Subject)
SC 13D - MERIDIAN BIOSCIENCE INC (0000794172) (Subject)
Live finance-specific insights
Shareholders to Receive $34.00 Per Share in Cash, Providing Immediate, Compelling and Certain Value Transaction Follows Deliberate Review, Including Outreach to Potential Strategic and Financial Partners CINCINNATI and SEOUL, South Korea, July 7, 2022 /PRNewswire/ -- Meridian Bioscience, Inc. ("Meridian" or the "Company") (NASDAQ:VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, and SD Biosensor, Inc. ("SDB") (KOSE: A137310) and SJL Partners LLC ("SJL") (collectively, the "Consortium") announced today that they have entered into a definitive merger agreement whereby a newly formed affiliate vehicle of the Consortium will acquire Meridian in an a
CINCINNATI, May 6, 2022 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced financial results for the second quarter ended March 31, 2022. Second Quarter Fiscal 2022 Highlights (Comparison to Second Quarter Fiscal 2021): Consolidated net revenues totaled $111.2 million, the highest in Company history, with both segments ahead of expectationsLife Science segment delivered record net revenues of $70.1 millionDiagnostics segment net revenues increased 29% year-over-year to a record $41.1 millionLaunched Lyo-Ready™ sample specific master mixes for bloodResumed
CINCINNATI, Ohio, May 2, 2022 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ:VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today that it has acquired, through its subsidiary Meridian Life Science, Inc., substantially all of the assets of EUPROTEIN Inc. The transaction closed on April 30, 2022. EUPROTEIN Inc. offers custom development and production of high-quality bioresearch reagents, with a particular focus on human and other mammalian proteins and recombinant monoclonal antibodies. This acquisition will help
CINCINNATI, April 7, 2022 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ:VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, today provided preliminary net revenues results for its second quarter of fiscal 2022. Preliminary unaudited net revenues for the second quarter of fiscal 2022 are expected to be between $109 million and $113 million, above Meridian's expectations and a record for the Company. Individually, both of the Company's segments are also expected to have record net revenues in the quarter with the Diagnostics segme
CINCINNATI, Feb. 4, 2022 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced financial results for the first quarter ended December 31, 2021. First Quarter Fiscal 2022 Highlights (Comparison to First Quarter Fiscal 2021): Consolidated net revenues of $88.3 million, second best in company history with both segments ahead of expectations Life Science segment delivered net revenues of $55.1 million Diagnostics segment net revenues increased 10% year-over-year to $33.2 million Launched first Lyo-Ready™ sample-specific master mix for saliva-based assays Receive
CINCINNATI, Jan. 10, 2022 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ:VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, will report first quarter 2022 financial results Friday, February 4, 2022. Jack Kenny, Chief Executive Officer, will host a conference call beginning at 10:00 a.m. Eastern Time to discuss the results and answer questions. To participate in the live call by webcast, join directly here or visit investor.meridianbioscience.com for the link. If you are unable to join the webcast, you may join by telephone. Fr
CINCINNATI, Nov. 12, 2021 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced financial results for the fourth quarter and fiscal year ended September 30, 2021. Fourth Quarter 2021 Highlights (Comparison to Fourth Quarter Fiscal 2020): Consolidated net revenues of $76.2 million, up 19% year-over-year Life Science segment delivered net revenues of $41.9 million, up 22% year-over-year Diagnostics segment net revenues increased 15% year-over-year to $34.3 million Launched Air-Dryable™ sample specific master mixes for stool, blood and urine and Air-Dryable™ LA
CINCINNATI, Oct. 14, 2021 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ:VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, will report fourth quarter and full year 2021 financial results Friday, November 12, 2021. Jack Kenny, Chief Executive Officer, and Bryan Baldasare, Executive Vice President and Chief Financial Officer, will host a conference call beginning at 10:00 a.m. Eastern Time to discuss the results and answer questions. Meridian is introducing a live webcast for this and future earnings calls. This will provide
CINCINNATI, Aug. 06, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced financial results for the third quarter ended June 30, 2021. Third Quarter 2021 Highlights (Comparison to Third Quarter Fiscal 2020):• Consolidated net revenues of $63.5 million, down 25% year-over-year, but up 31% from pre-pandemic third quarter fiscal 2019• Diagnostics segment net revenues increased 44% year-over-year to $31.2 million• Life Science segment net revenues decreased 49% year-over-year to $32.3 million• Re-Submitted Emergency Use Authorization ("EUA") with U.S. Food and Drug Administration ("FDA") for Revogene® SARS-CoV-2 assay• Launched Lyo-Ready master mixes for loop-media
Live Leadership Updates
Mr. Harris was the lead battery responsible engineer at SpaceX, leading the engineering team that developed the battery systems of the Falcon 9 rocket, Cargo Dragon, and Crew Dragon spacecraft Appointment to Advisory Council bolsters VivoPower's power systems and battery engineering expertise across its sovereign AI data center platform, including operational Nordic sites as well as for Tembo, its electric vehicle business LONDON, June 02, 2026 (GLOBE NEWSWIRE) -- VivoPower PLC (NASDAQ:VIVO) ("VivoPower" or the "Company"), a B Corp-certified global developer and owner of powered land and data center infrastructure for AI compute applications, today announced the appointment of Porter Har
Ms. Mustafa brings a track record from a 23-year tenure at Microsoft, where she headed Global Sales & Partnerships for Industrial Metaverse Core, in the Cloud & AI division of Microsoft Based between New York and Abu Dhabi, she was also formerly head of global partnerships for Core 42, which is part of G42, the Abu Dhabi headquartered AI group backed by Mubadala, Microsoft, Silverlake, and the Dalio Family Office LONDON, April 07, 2026 (GLOBE NEWSWIRE) -- VivoPower PLC (NASDAQ:VIVO) ("VivoPower" or the "Company"), a B Corp-certified global developer and owner of powered land and data center infrastructure for AI compute applications, today announced the appointment of Khadija Mustafa to
CINCINNATI, Dec. 2, 2021 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ:VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today that Bryan Baldasare, Executive Vice President, Chief Financial Officer, and Secretary, will retire from Meridian effective December 31, 2021. The Company is engaging an executive search firm in the recruitment of a new chief financial officer. The Company appointed Julie Smith to the position of Senior Vice President, Controller, effective December 6, 2021, and principal accounting officer, effective January 1, 2022.
CINCINNATI, Nov. 24, 2021 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ:VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today that David Phillips, Chairman of the Board of Directors, will retire from the Board of Directors and not seek re-election when his term ends in January 2022. The Board of Directors will elect a new chair when Mr. Phillips' term expires and will not replace the vacated seat, which will reduce the number of directors to eight. Mr. Phillips joined the Meridian Board of Directors in 2000 and ha